Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations

Thromb Haemost. 2008 May;99(5):916-24. doi: 10.1160/TH07-09-0565.

Abstract

Reduced plasma survival of von Willebrand factor (VWF) may contribute towards the pathogenesis of type 1 von Willebrand disease (VWD). However, little is known about mechanism(s) of VWF clearance and factors that may affect it. The half-life of VWF-related parameters following the administration of DDAVP was measured in 26 patients with type 1 VWD and 10 haemophilia A controls. Binding of lectins Ricinus communis (RCA-I) and Erythina crystagalli (ECA) agglutinins to VWF and VWF susceptibility to ADAMTS-13-mediated proteolysis were investigated. Sequence analysis of targeted regions of the VWF gene was performed to inspect for mutations that have been associated with increased clearance. Post-DDAVP clearance of VWF was increased approximately three-fold in the type 1 VWD cohort overall. However this was not shown to consistently associate with steady-state VWF antigen (VWF:Ag) levels. Furthermore, increased VWF clearance was not consistently associated with increased ratios of VWF propeptide (VWFpp) to VWF:Ag indicating that a normal ratio does not necessarily reflect normal post-DDAVP survival in type 1 VWD patients. RCA-I and ECA binding to VWF were increased in type 1 VWD patients and, although inversely correlated with VWF levels, this was independent of VWF clearance. There was no association between VWF clearance and ADAMTS-13-mediated proteolysis. Three novel candidate mutations with an increased clearance phenotype were identified. The data are consistent with heterogeneity in pathogenic mechanisms in type 1 VWD and are consistent with type 1 VWD representing a complex genetic trait.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • ADAM Proteins / blood*
  • ADAMTS13 Protein
  • Cohort Studies
  • DNA Mutational Analysis
  • Deamino Arginine Vasopressin / administration & dosage*
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Glycosylation
  • Half-Life
  • Hemostatics / administration & dosage*
  • Humans
  • Infusions, Intravenous
  • Male
  • Mutation*
  • Phenotype
  • Plant Lectins / metabolism
  • Protein Binding
  • Protein Precursors / blood
  • Protein Processing, Post-Translational / drug effects*
  • Treatment Outcome
  • von Willebrand Diseases / blood
  • von Willebrand Diseases / drug therapy*
  • von Willebrand Diseases / genetics
  • von Willebrand Factor / genetics
  • von Willebrand Factor / metabolism*

Substances

  • Hemostatics
  • Plant Lectins
  • Protein Precursors
  • Ricinus communis agglutinin-1
  • von Willebrand Factor
  • von Willebrand factor propolypeptide
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human
  • Deamino Arginine Vasopressin